.png)
Alzheimer’s Disease Market By Drug Class And Disctribution Channel - Global Industry Analysis And Forecast To 2023
Published On : May 2022 Pages : 190 Category: Biotechnology Report Code : HC05794
SEGMENTS & REGIONS:
- Regions: North America, Europe, Asia- Pacific, Latin America, Middle East & Africa
Regional Outlook and Trend Analysis
The regional market of North America represented the most elevated share in the worldwide market for Alzheimer's disease in 2017 as a result of the vast number of patients experiencing the Alzheimer's and developing awareness among the local populace about the treatment. The North America market for Alzheimer's disease remained at general valuation of US$1.7 bn in 2022 and is assessed to grow tremendously over the forecast period.
Major Key Player’s
The leading players in the market are Johnson & Johnson, ONO PHARMACEUTICAL CO LTD, Merz Pharma GmbH & Co. KGaA, Daiichi Sankyo, Novartis, Eisai, and Allergan. The major players in the market are profiled in detail in view of qualities, for example, company portfolio, business strategies, financial overview, recent developments, and share of the overall industry.
Drug Class Outlook and Trend Analysis
On the basis of class, the Alzheimer's disease market can be divided into cholinergic, memantine and combined drugs. Memantine drug type commanded the worldwide market for Alzheimer's disease in the year 2017 attributable to vast scale expiry of patents of major products and a limited number of medications to treat Alzheimer's. This portion of memantine drug is anticipated to command the market in the coming a long time of the conjecture time frame.
Industry Outlook and Trend Analysis
The Alzheimer’s disease Market was worth USD 2.89 billion in 2017 and is expected to reach approximately USD 5.51 billion by 2023, while registering itself at a compound annual growth rate (CAGR) of 7.45% during the forecast period. The major driving component for the improvement of the worldwide Alzheimer's market is the expanding pervasiveness of the disease in the emerging nations in the West. Various neurodegenerative disease have turned out to be progressively common in the nations, for example, the U.S. in the previous couple of years, prompting a relentless help from the legislature to create drugs for treatment. This has brought about a very ideal economic situation for the drug producers of the Alzheimer's disease and thus driving the development of the market in the area. Likewise there is an expanding awareness among individuals about treatment of the Alzheimer's disease which has additionally contributed in the driving the development of the market.
Distribution Channel Outlook and Trend Analysis
Based on distribution channels, the market has been segmented into three segments including hospital pharmacy, retail pharmacy, and online sales. The hospital pharmacy is leading segment of the market and is anticipated to continue its development over the forecast period. Increasing old age population and higher incidences of neurodegenerative diseases are two major factors that boost the market growth.
The Alzheimer’s disease Market is segmented as follows-
By Drug Class:
- Memantine
- Cholinergic
- Combined Drug
- Others
By Distribution Channel:
- Retail Pharmacy
- Hospital Pharmacy
- Online Sales
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- UK
- France
- Russia
- Italy
- Rest of Europe
- Asia-Pacific
- China
- Japan
- South Korea
- India
- Southeast Asia
- Rest of Asia-Pacific
- South America
- Brazil
- Argentina
- Columbia
- South Africa
- Rest of South America
- Middle East and Africa
- Saudi Arabia
- UAE
- Egypt
- Nigeria
- South Africa
- Rest of MEA
Some of the key questions answered by the report are:
- What was the market size in 2017 and forecast from 2017 to 2023?
- What will be the industry market growth from 2017 to 2023?
- What are the major drivers, restraints, opportunities, challenges, and industry trends and their impact on the market forecast?
- What are the major segments leading the market growth and why?
- Which are the leading players in the market and what are the major strategies adopted by them to sustain the market competition?
Market Classification
· Alzheimer’s Drugs Market, By Drug Class, Estimates and Forecast, 2014-2023 ($Million)
· Cholinergic
· Memantine
· Combined Drug
· Other Drug Classes
· Alzheimer’s Drugs Market, By Distribution Channel, Estimates and Forecast, 2014-2023 ($Million)
· Hospital Pharmacy
· Retail Pharmacy
· Online Sales
· Alzheimer’s Drugs Market, By Region, Estimates and Forecast, 2014-2023 ($Million)
· North America
§ North America Alzheimer’s Drugs Market, By Country
o U.S. Alzheimer’s Drugs Market
o Canada Alzheimer’s Drugs Market
o Mexico Alzheimer’s Drugs Market
· Europe
§ Europe Alzheimer’s Drugs Market, By Country
o Germany Alzheimer’s Drugs Market
o UK Alzheimer’s Drugs Market
o France Alzheimer’s Drugs Market
o Russia Alzheimer’s Drugs Market
o Italy Alzheimer’s Drugs Market
o Rest of Europe Alzheimer’s Drugs Market
· Asia-Pacific
§ Asia-Pacific Alzheimer’s Drugs Market, By Country
o China Alzheimer’s Drugs Market
o Japan Alzheimer’s Drugs Market
o South Korea Alzheimer’s Drugs Market
o India Alzheimer’s Drugs Market
o Southeast Asia Alzheimer’s Drugs Market
o Rest of Asia-Pacific Alzheimer’s Drugs Market
· South America
§ South America Alzheimer’s Drugs Market
o Brazil Alzheimer’s Drugs Market
o Argentina Alzheimer’s Drugs Market
o Columbia Alzheimer’s Drugs Market
o South Africa Alzheimer’s Drugs Market
o Rest of South America Alzheimer’s Drugs Market
· Middle East and Africa
§ Middle East and Africa Alzheimer’s Drugs Market
o Saudi Arabia Alzheimer’s Drugs Market
o UAE Alzheimer’s Drugs Market
o Egypt Alzheimer’s Drugs Market
o Nigeria Alzheimer’s Drugs Market
o South Africa Alzheimer’s Drugs Market
o Rest of MEA Alzheimer’s Drugs Market
Table of Contents
1. Introduction
1.1. Report Description
1.2. Research Methodology
1.2.1. Secondary Research
1.2.2. Primary Research
2. Executive Summary
2.1. Key Highlights
3. Market Overview
3.1. Introduction
3.1.1. Market Definition
3.1.2. Market Segmentation
3.2. Market Dynamics
3.2.1. Drivers
3.2.2. Restraints
3.2.3. Opportunities
3.2.3.1. Emerging Markets to Offer Lucrative Growth Opportunities
4. Market Analysis by Regions
4.1. North America (United States, Canada and Mexico)
4.1.1. United States Market States and Outlook (2017-2023)
4.1.2. Canada Market States and Outlook (2017-2023)
4.1.3. Mexico Market States and Outlook (2017-2023)
4.2. Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
4.2.1. Germany Market States and Outlook (2017-2023)
4.2.2. France Market States and Outlook (2017-2023)
4.2.3. UK Market States and Outlook (2017-2023)
4.2.4. Russia Market States and Outlook (2017-2023)
4.2.5. Italy Market States and Outlook (2017-2023)
4.2.6. Rest of Europe Market States and Outlook (2017-2023)
4.3. Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Rest of Asia-Pacific)
4.3.1. China Market States and Outlook (2017-2023)
4.3.2. Japan Market States and Outlook (2017-2023)
4.3.3. Korea Market States and Outlook (2017-2023)
4.3.4. India Market States and Outlook (2017-2023)
4.3.5. Rest of Asia-Pacific Market States and Outlook (2017-2023)
4.4. South America (Brazil, Argentina, Columbia and Rest of South America)
4.4.1. Brazil Market States and Outlook (2017-2023)
4.4.2. Argentina Market States and Outlook (2017-2023)
4.4.3. Columbia Market States and Outlook (2017-2023)
4.4.4. Rest of South America Market States and Outlook (2017-2023)
4.5. Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa and Rest of MEA)
4.5.1. Saudi Arabia Market States and Outlook (2017-2023)
4.5.2. UAE Market States and Outlook (2017-2023)
4.5.3. Egypt Market States and Outlook (2017-2023)
4.5.4. Nigeria Market States and Outlook (2017-2023)
4.5.5. South Africa Market States and Outlook (2017-2023)
4.5.6. Rest of MEA Market States and Outlook (2017-2023)
5. Alzheimer’s Disease Market, By Drug Class
5.1. Introduction
5.2. Global Alzheimer’s Disease Sales, Revenue and Market Share by Drug Class (2017-2027)
5.2.1. Global Alzheimer’s Disease Sales and Sales Share by Drug Class (2017-2027)
5.2.2. Global Alzheimer’s Disease Revenue and Revenue Share by Drug Class (2017-2027)
5.3. Cholinergic
5.3.1. Global Cholinergic Sales and Growth Rate (2017-2027)
5.4. Memantine
5.4.1. Global Memantine Sales and Growth Rate (2017-2027)
5.5. Combined Drug
5.5.1. Global Combined Drug Sales and Growth Rate (2017-2027)
5.6. Other Drug Classes
5.6.1. Global Drug Classes Sales and Growth Rate (2017-2027)
6. Alzheimer’s Disease Market, By Distribution Channel
6.1. Introduction
6.2. Global Alzheimer’s Disease Sales, Revenue and Market Share by Distribution Channel (2017-2027)
6.2.1. Global Alzheimer’s Disease Sales and Sales Share by Distribution Channel (2017-2027)
6.2.2. Global Alzheimer’s Disease Revenue and Revenue Share by Distribution Channel (2017-2027)
6.3. Hospital Pharmacy
6.3.1. Global Hospital Pharmacy Sales and Growth Rate (2017-2027)
6.4. Retail Pharmacy
6.4.1. Global Retail Pharmacy Sales and Growth Rate (2017-2027)
6.5. Online Sales
6.5.1. Global Online Sales and Growth Rate (2017-2027)
7. Alzheimer’s Disease Market, By Region
7.1. Introduction
7.2. Global Alzheimer’s Disease Sales, Revenue and Market Share by Regions
7.2.1. Global Alzheimer’s Disease Sales by Regions (2017-2027)
7.2.2. Global Alzheimer’s Disease Revenue by Regions (2017-2027)
7.3. North America Alzheimer’s Disease by Countries
7.3.1. North America Alzheimer’s Disease Sales and Growth Rate (2017-2027)
7.3.2. North America Alzheimer’s Disease Revenue and Growth Rate (2017-2027)
7.3.3. North America Alzheimer’s Disease Sales by Countries (2017-2027)
7.3.4. North America Alzheimer’s Disease Revenue (Million USD) by Countries (2017-2027)
7.3.5. U.S.
7.3.5.1. United States Alzheimer’s Disease Sales and Growth Rate (2017-2027)
7.3.5.2. United States Alzheimer’s Disease Revenue (Millions USD) and Growth Rate (2017-2027)
7.3.6. Canada
7.3.6.1. Canada Alzheimer’s Disease Sales and Growth Rate (2017-2027)
7.3.6.2. Canada Alzheimer’s Disease Sales (Millions USD) and Growth Rate (2017-2027)
7.3.7. Mexico
7.3.7.1. Mexico Alzheimer’s Disease Sales and Growth Rate (2017-2027)
7.3.7.2. Mexico Alzheimer’s Disease Revenue (Millions USD) and Growth Rate (2017-2027)
7.4. Europe Alzheimer’s Disease by Countries
7.4.1. Europe Alzheimer’s Disease Sales and Growth Rate (2017-2027)
7.4.2. Europe Alzheimer’s Disease Revenue and Growth Rate (2017-2027)
7.4.3. Europe Alzheimer’s Disease Sales by Countries (2017-2027)
7.4.4. Europe Alzheimer’s Disease Revenue (Million USD) by Countries (2017-2027)
7.4.5. Germany
7.4.5.1. Germany Alzheimer’s Disease Sales and Growth Rate (2017-2027)
7.4.5.2. Germany Alzheimer’s Disease Revenue (Millions USD) and Growth Rate (2017-2027)
7.4.6. UK
7.4.6.1. UK Alzheimer’s Disease Sales and Growth Rate (2017-2027)
7.4.6.2. UK Alzheimer’s Disease Revenue (Millions USD) and Growth Rate (2017-2027)
7.4.7. France
7.4.7.1. France Alzheimer’s Disease Sales and Growth Rate (2017-2027)
7.4.7.2. France Alzheimer’s Disease Revenue (Millions USD) and Growth Rate (2017-2027)
7.4.8. Russia
7.4.8.1. Russia Alzheimer’s Disease Sales and Growth Rate (2017-2027)
7.4.8.2. Russia Alzheimer’s Disease Revenue (Millions USD) and Growth Rate (2017-2027)
7.4.9. Italy
7.4.9.1. Italy Alzheimer’s Disease Sales and Growth Rate (2017-2027)
7.4.9.2. Italy Alzheimer’s Disease Revenue (Millions USD) and Growth Rate (2017-2027)
7.4.10. Rest of Europe
7.4.10.1. Rest of Europe Alzheimer’s Disease Sales and Growth Rate (2017-2027)
7.4.10.2. Rest of Europe Alzheimer’s Disease Revenue (Millions USD) and Growth Rate (2017-2027)
7.5. Asia-Pacific
7.5.1. Asia-Pacific Alzheimer’s Disease Sales and Growth Rate (2017-2027)
7.5.2. Asia-Pacific Alzheimer’s Disease Revenue and Growth Rate (2017-2027)
7.5.3. Asia-Pacific Alzheimer’s Disease Sales by Countries (2017-2027)
7.5.4. Asia-Pacific Alzheimer’s Disease Revenue (Million USD) by Countries (2017-2027)
7.5.5. China
7.5.5.1. China Alzheimer’s Disease Sales and Growth Rate (2017-2027)
7.5.5.2. China Alzheimer’s Disease Revenue (Millions USD) and Growth Rate (2017-2027)
7.5.6. Japan
7.5.6.1. Japan Alzheimer’s Disease Sales and Growth Rate (2017-2027)
7.5.6.2. Japan Alzheimer’s Disease Revenue (Millions USD) and Growth Rate (2017-2027)
7.5.6.3.
7.5.7. Korea
7.5.7.1. Korea Alzheimer’s Disease Sales and Growth Rate (2017-2027)
7.5.7.2. Korea Alzheimer’s Disease Revenue (Millions USD) and Growth Rate (2017-2027)
7.5.8. India
7.5.8.1. India Alzheimer’s Disease Sales and Growth Rate (2017-2027)
7.5.8.2. India Alzheimer’s Disease Revenue (Millions USD) and Growth Rate (2017-2027)
7.5.9. Southeast Asia
7.5.9.1. Southeast Asia Alzheimer’s Disease Sales and Growth Rate (2017-2027)
7.5.9.2. Southeast Asia Alzheimer’s Disease Revenue (Millions USD) and Growth Rate (2017-2027)
7.5.10. Rest of Asia-Pacific
7.5.10.1. Rest of Asia-Pacific Alzheimer’s Disease Sales and Growth Rate (2017-2027)
7.5.10.2. Rest of Asia-Pacific Alzheimer’s Disease Revenue (Millions USD) and Growth Rate (2017-2027)
7.6. South America
7.6.1. South America Alzheimer’s Disease Sales and Growth Rate (2017-2027)
7.6.2. South America Alzheimer’s Disease Revenue and Growth Rate (2017-2027)
7.6.3. South America Alzheimer’s Disease Sales by Countries (2017-2027)
7.6.4. South America Alzheimer’s Disease Revenue (Million USD) by Countries (2017-2027)
7.6.5. Brazil
7.6.5.1. Brazil Alzheimer’s Disease Sales and Growth Rate (2017-2027)
7.6.5.2. Brazil Alzheimer’s Disease Revenue (Millions USD) and Growth Rate (2017-2027)
7.6.6. Argentina
7.6.6.1. Argentina Alzheimer’s Disease Sales and Growth Rate (2017-2027)
7.6.6.2. Argentina Alzheimer’s Disease Revenue (Millions USD) and Growth Rate (2017-2027)
7.6.7. Columbia
7.6.7.1. Columbia Alzheimer’s Disease Sales and Growth Rate (2017-2027)
7.6.7.2. Columbia Alzheimer’s Disease Revenue (Millions USD) and Growth Rate (2017-2027)
7.6.8. Rest of South America
7.6.8.1. Rest of South America Alzheimer’s Disease Sales and Growth Rate (2017-2027)
7.6.8.2. Rest of South America Alzheimer’s Disease Revenue (Millions USD) and Growth Rate (2017-2027)
7.7. Middle East and Africa
7.7.1. Middle East and Africa Alzheimer’s Disease Sales and Growth Rate (2017-2027)
7.7.2. Middle East and Africa Alzheimer’s Disease Revenue and Growth Rate (2017-2027)
7.7.3. Middle East and Africa Alzheimer’s Disease Sales by Countries (2017-2027)
7.7.4. Middle East and Africa Alzheimer’s Disease Revenue (Million USD) by Countries (2017-2027)
7.7.5. Saudi Arabia
7.7.5.1. Saudi Arabia Alzheimer’s Disease Sales and Growth Rate (2017-2027)
7.7.5.2. Saudi Arabia Alzheimer’s Disease Revenue (Millions USD) and Growth Rate (2017-2027)
7.7.6. United Arab Emirates
7.7.6.1. United Arab Emirates Alzheimer’s Disease Sales and Growth Rate (2017-2027)
7.7.6.2. United Arab Emirates Alzheimer’s Disease Revenue (Millions USD) and Growth Rate (2017-2027)
7.7.7. Egypt
7.7.7.1. Egypt Alzheimer’s Disease Sales and Growth Rate (2017-2027)
7.7.7.2. Egypt Alzheimer’s Disease Revenue (Millions USD) and Growth Rate (2017-2027)
7.7.8. Nigeria
7.7.8.1. Nigeria Alzheimer’s Disease Sales and Growth Rate (2017-2027)
7.7.8.2. Nigeria Alzheimer’s Disease Revenue (Millions USD) and Growth Rate (2017-2027)
7.7.9. South Africa
7.7.9.1. South Africa Alzheimer’s Disease Sales and Growth Rate (2017-2027)
7.7.9.2. South Africa Alzheimer’s Disease Revenue (Millions USD) and Growth Rate (2017-2027)
7.7.10. Rest of Middle East and Africa
7.7.10.1. Rest of Middle East and Africa Alzheimer’s Disease Sales and Growth Rate (2017-2027)
7.7.10.2. Rest of Middle East and Africa Alzheimer’s Disease Revenue (Millions USD) and Growth Rate (2017-2027)
8. Company Profiles
8.1. Allergan plc
8.1.1. Business Overview
8.1.2. Product Portfolio
8.1.3. Strategic Developments
8.1.4. Sales, Revenue and Market Share
8.2. Novartis AG
8.2.1. Business Overview
8.2.2. Product Portfolio
8.2.3. Strategic Developments
8.2.4. Sales, Revenue and Market Share
8.3. Eisai Co Ltd
8.3.1. Business Overview
8.3.2. Product Portfolio
8.3.3. Strategic Developments
8.3.4. Sales, Revenue and Market Share
8.4. Johnson & Johnson
8.4.1. Business Overview
8.4.2. Product Portfolio
8.4.3. Strategic Developments
8.4.4. Sales, Revenue and Market Share
8.5. Daiichi Sankyo Company Limited
8.5.1. Business Overview
8.5.2. Product Portfolio
8.5.3. Strategic Developments
8.5.4. Sales, Revenue and Market Share
8.6. Ono Pharmaceutical Co Ltd
8.6.1. Business Overview
8.6.2. Product Portfolio
8.6.3. Strategic Developments
8.6.4. Sales, Revenue and Market Share
8.7. H Lundbeck A/S
8.7.1. Business Overview
8.7.2. Product Portfolio
8.7.3. Strategic Developments
8.7.4. Sales, Revenue and Market Share
8.8. Merz Holding GmbH & Co KG
8.8.1. Business Overview
8.8.2. Product Portfolio
8.8.3. Strategic Developments
8.8.4. Sales, Revenue and Market Share
9. Global Alzheimer’s Disease Market Competition, by Manufacturer
9.1. Global Alzheimer’s Disease Sales and Market Share by Manufacturer (2017-2017)
9.2. Global Alzheimer’s Disease Revenue and Market Share by Manufacturer (2017-2017)
9.3. Global Alzheimer’s Disease Price by Manufacturer (2017-2017)
9.4. Top 5 Alzheimer’s Disease Manufacturer Market Share
9.5. Market Competition Trend
10. Alzheimer’s Disease Market Forecast (2027-2023)
10.1. Global Alzheimer’s Disease Sales, Revenue (Millions USD) and Growth Rate (2027-2023)
10.2. Alzheimer’s Disease Market Forecast by Regions (2027-2023)
10.2.1. North America Alzheimer’s Disease Market Forecast (2027-2023)
10.2.1.1. United States Alzheimer’s Disease Market Forecast (2027-2023)
10.2.1.2. Canada Alzheimer’s Disease Market Forecast (2027-2023)
10.2.1.3. Mexico Alzheimer’s Disease Market Forecast (2027-2023)
10.2.2. Europe Alzheimer’s Disease Market Forecast (2027-2023)
10.2.2.1. Germany Alzheimer’s Disease Market Forecast (2027-2023)
10.2.2.2. United Kingdom Alzheimer’s Disease Market Forecast (2027-2023)
10.2.2.3. France Alzheimer’s Disease Market Forecast (2027-2023)
10.2.2.4. Russia Alzheimer’s Disease Market Forecast (2027-2023)
10.2.2.5. Italy Alzheimer’s Disease Market Forecast (2027-2023)
10.2.2.6. Rest of the Europe Alzheimer’s Disease Market Forecast (2027-2023)
10.2.3. Asia-Pacific Alzheimer’s Disease Market Forecast (2027-2023)
10.2.3.1. China Alzheimer’s Disease Market Forecast (2027-2023)
10.2.3.2. Japan Alzheimer’s Disease Market Forecast (2027-2023)
10.2.3.3. Korea Alzheimer’s Disease Market Forecast (2027-2023)
10.2.3.4. India Alzheimer’s Disease Market Forecast (2027-2023)
10.2.3.5. Southeast Asia Alzheimer’s Disease Market Forecast (2027-2023)
10.2.3.6. Rest of Asia-Pacific Alzheimer’s Disease Market Forecast (2027-2023)
10.2.4. South America Alzheimer’s Disease Market Forecast (2027-2023)
10.2.4.1. Brazil Alzheimer’s Disease Market Forecast (2027-2023)
10.2.4.2. Argentina Alzheimer’s Disease Market Forecast (2027-2023)
10.2.4.3. Columbia Alzheimer’s Disease Market Forecast (2027-2023)
10.2.4.4. Rest of South America Alzheimer’s Disease Market Forecast (2027-2023)
10.2.5. Middle East and Africa Alzheimer’s Disease Market Forecast (2027-2023)
10.2.5.1. Saudi Arabia Alzheimer’s Disease Market Forecast (2027-2023)
10.2.5.2. UAE Alzheimer’s Disease Market Forecast (2027-2023)
10.2.5.3. Egypt Alzheimer’s Disease Market Forecast (2027-2023)
10.2.5.4. Nigeria Alzheimer’s Disease Market Forecast (2027-2023)
10.2.5.5. South Africa Alzheimer’s Disease Market Forecast (2027-2023)
10.2.5.6. Rest of MEA Alzheimer’s Disease Market Forecast (2027-2023)
10.3. Alzheimer’s Disease Market Forecast by Drug Class (2027-2023)
10.3.1. Global Alzheimer’s Disease Sales Forecast by Drug Class (2027-2023)
10.3.2. Global Alzheimer’s Disease Sales Market Share Forecast by Drug Class (2027-2023)
10.4. Alzheimer’s Disease Market Forecast by Distribution Channel (2027-2023)
10.4.1. Global Alzheimer’s Disease Sales Forecast by Distribution Channel (2027-2023)
10.4.2. Global Alzheimer’s Disease Sales Market Share Forecast by Distribution Channel (2027-2023)
*You can glance through the list of Tables and Figures when you view the sample copy of Alzheimer’s disease Market.
List of Tables
*You can glance through the list of Tables and Figures when you view the sample copy of Alzheimer’s disease Market.
Research Methodology
We use both primary as well as secondary research for our market surveys, estimates and for developing forecast. Our research process commence by analyzing the problem which enable us to design the scope for our research study. Our research process is uniquely designed with enough flexibility to adjust according to changing nature of products and markets, while retaining core element to ensure reliability and accuracy in research findings. We understand both macro and micro-economic factors to evaluate and forecast different market segments.
Data Mining
Data is extensively collected through various secondary sources such as annual reports, investor presentations, SEC filings, and other corporate publications. We also refer trade magazines, technical journals, paid databases such as Factiva and Bloomberg, industry trade journals, scientific journals, and social media data to understand market dynamics and industry trends. Further, we also conduct primary research to understand market drivers, restraints, opportunities, challenges, and competitive scenario to build our analysis.
Data Collection Matrix
|
Data Collection Matrix |
Supply Side |
Demand Side |
|
Primary Data Sources |
|
|
|
Secondary Data Sources |
|
|
Market Modeling and Forecasting
We use epidemiology and capital equipment-based models to forecast market size of different segments at country and regional level.
- Epidemiology-based Forecasting Model: This method uses epidemiology data gathered through various publications and from physicians to estimate population of patients, flow of treatment of individual disease and therapies. The data collected through this method includes statics on incidence of disease, population suffering from disease, and treatment population. This method is used to understand:
- Number of patients for particular device or medical procedure and
- Repeated use of particular device depending on health and condition of patient
- Capital-based Forecasting Model: This method of forecasting is based on number of replacements, installed-based and new sales of capital equipment used in various healthcare and diagnostic centers. These three parameters are calculated and forecast is developed. Installation base is calculated as average number of units per facility; while sales for particular year is calculated from number of new and replace units. Secondary data is collected through various supply chain intermediaries and opinion leaders to arrive at installation and sales rate. These techniques help our analysts in validating market and developed market estimates and forecast.
We do forecast on basis of several parameters such as market drivers, market opportunities, industry trends government regulations, raw materials supply and trade dynamics to ensure relevance of forecast with market scenario. With increasing need to granulized information, we used bottom-up methodology for forecasting where we evaluate each regional segment differently and combined all forecast to develop final market forecast.
Data Validation
We believe primary research is a very important tool in analyzing and forecasting different markets. In order to make sure accuracy of our findings, our team conducts primary interviews at every stage of research to gain deep insights into current business environment and future trends and key developments in market. This includes use of various methods such as telephonic interviews, focus groups, face to face interviews and questionnaires to validate our research from all aspects. We validate our data through primary research from key industry leaders such as CEO, product managers, marketing managers, suppliers, distributors, and consumers are frequently interviewed. These interviews provide valuable insights which help us to have better market understanding besides validating our estimates and forecast.
Data Triangulation
Industry Analysis
|
Qualitative Data |
Quantitative Data (2017-2025) |
|
|